Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, is dedicated to the discovery and development of therapies with an initial focus on cancer treatments. The company is headquartered in Rockville, Maryland.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-185.51M |
| Operating Margin | 0.00% |
| Return on Equity | -74.00% |
| Return on Assets | -95.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $14.74 |
| Price-to-Book | 1.26 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 1.36 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.34M |
| Float | 811,870 |
| % Insiders | 30.15% |
| % Institutions | 159.90% |
Volatility is currently expanding